IntroductionThis study aimed to investigate the dynamics of programmed death-ligand 1 (PD-L1) expression, spatial heterogeneity, and binding affinity of FDA-approved anti-PD-L1 antibodies (avelumab and atezolizumab) in gastric cancer. Additionally, we …
Cellular & Molecular Immunology, Published online: 07 June 2024; doi:10.1038/s41423-024-01185-3Chaperone- and PTM-mediated activation of IRF1 tames radiation-induced cell death and the inflammatory response
Science Immunology, Volume 9, Issue 96, June 2024.
Science Immunology, Volume 9, Issue 96, June 2024.
Science Immunology, Volume 9, Issue 96, June 2024.
Science Immunology, Volume 9, Issue 96, June 2024.
Science Immunology, Volume 9, Issue 96, June 2024.
Background
Tebentafusp, a bispecific (gp100xCD3) ImmTAC, significantly improved overall survival (OS) outcomes for HLA-A*02:01+ adult patients with untreated metastatic uveal melanoma (mUM) and showed promising survival in previously treated mUM with …
Background
The association between gut bacteria and the response to immune checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC) has been studied; however, multi-kingdom gut microbiome alterations and interactions in ICI-treated HCC cohorts ar…
The bispecific T cell-binding antibody blinatumomab (CD19/CD3) is widely and successfully used for the treatment of children with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Here, we report the efficacy of a single …
